ABT-122 is
a dual variable domain immunoglobulin targeting both TNF-alpha and IL-17. Mouse
studies showed the combination more efficacious than treatment with either
antibody.
Chung-Ming Hsieh and collegues presented the
following study [1427]: “Discovery and Characterization Of ABT-122, An
Anti-TNF/IL-17 DVDIg ™ Molecule As a Potential Therapeutic Candidate For
Rheumatoid Arthritis.” Results: “In acute mouse models in vivo, these DVD-Ig™
molecules also demonstrated potent inhibition of human TNF and IL-17 activity. The
DVD-Ig™ molecule with the best affinity and potency, as well as the longest
half-life in rat was designated ABT-122 for further development.” Conclusion: “Based
on the combined efficacy in a preclinical mouse arthritis model, the demonstrated
efficacy of TNF-targeted therapy in RA patients, and encouraging response to
IL-17 antibodies in RA clinical trials, we will be evaluating the efficacy and
safety profile of the anti-TNF/IL-17 DVD-Ig™ molecule in human RA clinical trials.”
The crucial
point will be: does better efficacy also mean more side effects. Perhaps we
have been too restrictive in combining biologics in the past. Maybe strategies using
more than one biologic agent, maybe in a certain sequence, will yield a
therapeutic approach with less side effects and more efficacy. But I’m dreaming
…
ABT-122 is
in preclinical evaluation, and let’s hope that we see clinical data soon. The
approach is interesting.
No comments:
Post a Comment